Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GD2-CAR PERSIST in Osteosarcoma or Neuroblastoma
NCT04539366Phase 1Suspended
- Sponsor
- National Cancer Institute
- Start
- Jan 2022
- Primary completion
- Dec 2040
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GD2-CAR-T cell in neuroblastoma and osteosarcoma (OS), sponsored by National Cancer Institute. Primary endpoints: Feasibility of producing GD2-CAR-expressing autologous T-lymphocytes (GD2CART) cells at 28 days, Incidence of adverse events at 15 years and 2 more. Started Jan 2022; status: suspended.
02
Drugs
GD2-CAR-T cell
03
Conditions
neuroblastomaosteosarcoma (OS)
Beyond the preview
Go deeper on NCT04539366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04539366.